Esperion (NASDAQ: ESPR) today announced that President and CEO, Sheldon Koenig, will present at Morgan Stanley’s 20th Annual Global Healthcare Conference and also participate in H.C. Wainwright’s Annual Global Investment Conference.
| Event: | Morgan Stanley 20th Annual Global Healthcare Conference |
| Date: | Monday, September 12th, 2022 |
| Time: | 9:20 AM (ET) |
| Format: | Presentation and 1:1 Meetings |
| Webcast: | Link |
| Event: | H.C. Wainwright Annual Global Investment Conference |
| Date: | September 12-14, 2022 |
| Time: | Presentation on Sept 13, 11:30 AM (ET) |
| Format: | Presentation and 1:1 Meetings |
| Webcast | Link |
A live audio webcast can be accessed on the investor and media section of the Esperion website at https://www.esperion.com/investor-relations/events. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company’s website for approximately 90 days.
Esperion Therapeutics
Esperion works hard to make our medicines easy to get, easy to take and easy to have. We discover, develop, and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. Esperion commercializes NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Tablets and is the leader in the development of convenient oral, once-daily non-statin LDL-cholesterol lowering drugs for patients with high levels of bad cholesterol. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc.
Contact:
Esperion Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.05 |
| Daily Change: | -0.01 -0.94 |
| Daily Volume: | 10,562,086 |
| Market Cap: | US$206.890M |
April 01, 2025 January 09, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
